Corcept Therapeutics director Wilson sells $882,985 in common stock

The insider sale is low-signal because it was pre-programmed, so the market should not over-interpret it. The real issue is that the stock has already re-rated ahead of hard commercialization proof, while earnings/revenue still show the business is not yet generating enough cash to comfortably support a triple-digit multiple. In that setup, even a modest regulatory wobble can compress the multiple faster than the operating business can grow into it.

The next 1-3 months are about FDA process risk, not the latest oncology headline. A clean review path keeps the name in a high-expectation wait-and-see range; any additional data request, label friction, or timeline slippage would likely hit the stock harder than the market is currently pricing. Approval would help, but the second-order question is uptake and reimbursement: the equity needs launch momentum, not just a green light.

The contrarian miss on the long side is that investors may be treating binary regulatory optionality like quasi-certain earnings power. That is dangerous at this valuation, especially after a large run and with a low-float profile that can reverse violently on disappointment. If the FDA stays on schedule and the data story keeps improving, shorts can get squeezed; if not, the stock could revert quickly toward a much lower multiple band.